RxDoctor Payments Data

Rodjawan Supakul, MD

Critical Care Medicine · Carmel, INNPI 1730463720

Payments from drug & device makers

What this record shows

16 manufacturers reported payments, led by Intuitive Surgical at 53.4% of the total.

$2,560in general payments, 2019–2025

Across 52 payments — averaging $49.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • GSK$386
  • Insmed, Inc.$178
  • Sanofi$139
  • AstraZeneca$105
  • Galderma Laboratories, L.p.$70
  • plus $317 from 10 others

What the payments were for

  • Travel & lodging$1,36653%
  • Food & beverage$1,19447%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,560 in reported general payments places this provider in the 75th percentile of 158 critical care medicine providers in Indiana.

See all critical care medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$68,390
Medicare patients
213
Services billed
649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$43,092
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$29,942
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$20,833
Advair HfaFluticasone Propion/Salmeterol37$19,385
SymbicortBudesonide/Formoterol Fumarate44$15,164
Spiriva RespimatTiotropium Bromide18$13,289
Breo ElliptaFluticasone/Vilanterol18$11,277
Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol17$8,671
Incruse ElliptaUmeclidinium Bromide17$6,003
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,570
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,131
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,979
Albuterol Sulfate HfaAlbuterol Sulfate97$1,979
Levocetirizine Dihydrochloride106$1,295
Montelukast Sodium53$1,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$386$65,94395 claims
AstraZenecaBreztri Aerosphere, Symbicort$105$45,10674 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$53$34,12142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 158 critical care medicine providers in Indiana.

Other critical care medicine in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →